Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
This study has implications that miR-141 as well as its target, ERBB4, as a potential target for treating trastuzumab-resistant breast cancers.
|
30746756 |
2019 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recent data suggest that HER4 unfavorably affects the endocrine treatment of postmenopausal breast cancer patients with tamoxifen and therefore might represent an additional therapeutic target in luminal breast cancer.
|
31139328 |
2019 |
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
MED1 mediates induction of cell proliferation and migration and the genes associated with it (JUN, FOS, EGFR, VEGF, MMP1, and ERBB4) in breast cancer, which is abrogated when used together with miR-191-inhibition.
|
30087366 |
2018 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
ErbB4 receptor polymorphism 2368A>C and risk of breast cancer.
|
30336339 |
2018 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
As heterodimerization and signaling partners for human epidermal growth factor receptor 2 (HER2), HER3/HER4 has been implicated in tumorigenic signaling and therapeutic resistance of breast cancer.
|
29127433 |
2018 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A number of single nucleotide polymorphisms (SNPs) in ERBB4 gene have been linked to increase the risk of breast cancer.
|
28508829 |
2018 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The Cancer Genome Atlas analysis revealed that somatic EGFR, receptor tyrosine-protein kinase erbB-2 (ERBB2), Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) gene mutations (ERBB family mutations) occur alone or co-occur with somatic mutations in the gene encoding the phosphatidylinositol 3-kinase (PI3K) catalytic subunit (PIK3CA) in 19% of human epidermal growth factor receptor 2 (HER2)-positive breast cancers.
|
28750640 |
2017 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overexpression of heregulin, a potent ligand that activates HER3 and HER4 receptors, plays a significant role in the development of chemotherapy resistance in breast cancer patients.
|
28797930 |
2017 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Levels of breast cancer 1 (BRCA1), EGF receptor (EGFR, also known as ERBB1), ERBB4, tubulointerstitial nephritis antigen-like 1 (TINAGL1) and ESR1 protein were examined with immunohistochemical analysis using immunofluorescence methods and confocal laser scanning microscopy.
|
28810691 |
2017 |
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In this study, we developed an anti-ErbB4 mAb (clone P6-1) that suppresses NRG-dependent activation of ErbB4 and examined its effect on breast cancer cell proliferation in the extracellular matrix.
|
26780728 |
2016 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
We identified 26 studies published between 1985 and 2016 and assessed the prognostic value of HER4 in breast cancer by either real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR, for mRNA levels) or immunohistochemistry (IHC, for protein levels).
|
27736797 |
2016 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The present study aimed to predict potential 3'‑UTR variants of ErbB4 that alter the target binding site of microRNAs (miRNAs) and to clarify the association of the potential variant with the risk of developing breast cancer.
|
27035115 |
2016 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Some miRNAs (e.g., miR-139-5p and miR-9) and their target gene SFRP1, as well as several other miRNAs (e.g., miR-375, miR-592, and miR-135a) and their target genes (e.g., ESR1 and ERBB4), might be crucial in the pathogenesis of primary breast cancer.
|
25680412 |
2015 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Failure to account for isoform-specific functions in previous studies may account for conflicting reports on the role of ERBB4 in breast cancer.
|
25516216 |
2014 |
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
High ErbB4 mRNA expression showed good prognosis with respect to breast cancer-specific survival
|
23100016 |
2014 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
The importance of Her4 expression is, however, still controversially discussed; there are few reports on the clinical significance of HER4, its splice variants, and cleaved HER4 intracellular domains (4ICD) which function differently depending on their localization in breast cancer.
|
25003574 |
2014 |
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Many of these transcripts were subsequently validated in a luminal breast cancer cell line that normally expresses ERBB4.
|
24829397 |
2014 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These data present the germ-line ERBB4 variant -815A>T as a novel prognostic marker in high-risk early breast cancer and indicate the presence of rare but potentially oncogenic somatic ERBB4 mutations in breast cancer.
|
25036186 |
2014 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overexpressing ERBB4 in cultured mammary epithelial cells or adding the ERBB4 ligand neuregulin 1 (NRG1) to breast cancer cell cultures promoted the expression of genes regulated by YAP, such as CTGF.
|
25492965 |
2014 |
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The prognostic and predictive impact of Her4 expression in breast cancer is basically unclear.
|
24063248 |
2013 |
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo.
|
23695025 |
2013 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Finally, knockdown of PIAS3 with siRNA partially rescued the inhibitory effect of the ErbB4 ICD on differentiation of MDA-MB-468 breast cancer and HC11 mammary epithelial cells.
|
22584572 |
2012 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
GWASDB |
A genome-wide association study identifies a breast cancer risk variant in ERBB4 at 2q34: results from the Seoul Breast Cancer Study.
|
22452962 |
2012 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
SNP rs13393577 at chromosome 2q34, located in the Epidermal Growth Factor Receptor 4 (ERBB4) gene, showed a consistent association with breast cancer risk with combined odds ratios (95% CI) of 1.53 (1.37-1.70) (combined P for trend = 8.8 × 10-14).
|
22452962 |
2012 |
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer.
|
21769435 |
2011 |